This clinical trial studies how an educational intervention about orchiectomy (surgical removal of one or both testicles) as an alternative to medical castration for patients who are already on medical castration (regular injections of a luteinizing hormone-releasing hormone [LHRH] agonist or antagonist) will impact the number of patients with prostate cancer willing to undergo an orchiectomy. Knowledge gained from this research may help researchers understand more about medical castration versus surgical castration (orchiectomy), which may benefit other patients with prostate cancer. It may also reduce the number of clinic visits and the overall costs of treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04705038.
PRIMARY OBJECTIVE:
I. To assess the effectiveness of education about orchiectomy on the willingness of prostate cancer patients on lifelong and long-term luteinizing hormone-releasing hormone (LHRH) agonist or antagonist therapy to undergo orchiectomy as an alternative to medical castration.
SECONDARY OBJECTIVES:
I. To assess the associations of demographics, body image, sexual health and function, decision regret, and costs with the willingness to receive education about as well as undergo an orchiectomy.
II. To assess change in body image perception, sexuality, and decision regret with orchiectomy.
III. To compare costs of medical versus surgical castration.
OUTLINE:
Patients' medical records may be reviewed. Patients may also participate in an educational session about orchiectomy, and complete 2 surveys about body image and sexual function and satisfaction at baseline. Patients also complete quality of life questionnaires at baseline and 6 months, and have costs associated with treatment collected for 1 year. Patients may speak with a urologist about surgical castration and choose to undergo an orchiectomy. Patients retake the 2 surveys at 6 months post-consent in addition to a 3rd survey about decision regret if they underwent an orchiectomy.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationUniversity of Chicago Comprehensive Cancer Center
Principal InvestigatorNabiel Ali Mir
